GET DAILY SIGNALSNephros (NEPH) Drops -15% in 30 Days Following Q3 Results and Margin Pressures
Key Takeaways
- Nephros (NEPH) shares declined roughly 15% over the last 30 days, falling from $3.29 on October 8, 2026, to $2.79 at the close on November 6, 2026.
- The pullback extends a broader slide of about 34% over the trailing three months, from an early-August level near $4.20.
- Third-quarter results released November 5 showed 18% year-over-year revenue growth and an earnings beat, yet margin pressure from tariffs, shipping costs, and revenue mix weighed on sentiment.
- Gross margin narrowed to about 58% in Q3 2026 from 61% a year earlier, reflecting higher tariff and shipping expenses plus faster growth in lower-margin service revenue.
- As a thinly traded micro-cap with a five-year beta near 1.75, NEPH tends to experience outsized price swings on relatively modest trading volume.
- Explore Nephros' Price Targets, Earnings, and Forecast pages for additional detail on valuation, fundamentals, and forward estimates.
Company Overview and Market Position
Nephros, Inc. is a water technology company that develops and sells high-performance, point-of-use filtration solutions for medical and commercial markets. In healthcare, its FDA-cleared ultrafilters are used in hospitals to help prevent infection from waterborne pathogens such as legionella and pseudomonas, and in dialysis centers to remove biological contaminants from water and bicarbonate concentrate. In commercial markets, the company supplies filters that improve taste and odor and reduce biofilm, lead, and scale build-up, serving foodservice, hospitality, convenience-store, and industrial customers.
Founded in 1997 and headquartered in South Orange, New Jersey, Nephros operates a small but profitable business: trailing twelve-month revenue of roughly $20.7 million with positive net income. Investors follow the stock for its recurring "programmatic" revenue model, its expanding active customer base, and its push into service and education offerings under a "products, service, education" strategy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, NEPH declined from $3.29 (October 8 close) to $2.79 (November 6 close), a drop of about 15%. The move was uneven: shares briefly traded above $3.60 in mid-October before selling off sharply in late October and again in the session following third-quarter earnings.
The recent decline is part of a longer downtrend. From an early-August close near $4.20, the stock has fallen roughly 34% through early November, and it now trades near the low end of its 52-week range of $2.66 to $6.42. After peaking around $4.70 to $4.87 in mid-August, the shares trended lower through September and October despite generally improving operating results.
Factors Behind the Recent Price Action
The most significant scheduled event was the release of third-quarter 2026 results on November 5. Nephros reported net revenue of approximately $5.62 million, up 18% year over year, with net income of about $0.5 million and adjusted EBITDA of roughly $0.6 million. Earnings of $0.05 per share exceeded consensus expectations, yet the stock fell 9.71% the following session.
A key driver of investor caution was margin compression. Gross margin declined to approximately 58% in Q3 2026 from 61% in the prior-year period, which management attributed to higher inventory, shipping, and handling costs—including tariff expense—as well as faster growth in service revenue, which carries a lower margin than product sales. The company also cited foreign currency movements and tariffs among ongoing cost pressures. From what I see, this margin detail helps explain why the market reacted the way it did despite the revenue beat.
Beyond fundamentals, NEPH's price action reflects its profile as a low-float micro-cap. With average daily volume near 39,000 shares and a beta near 1.75, relatively modest selling can produce large percentage moves, as seen in several elevated-volume sessions during the period. I’m watching this closely because liquidity remains a consistent factor in the stock’s volatility.
Quarterly Performance and Broader Context
Over the trailing three months, NEPH has given back most of the gains that carried it to its summer highs. After a strong first half, the shares peaked in August and have since re-rated lower even as the underlying business continued to grow. For the first nine months of 2026, revenue rose 20% to approximately $16.85 million and net income increased to about $1.85 million.
The broader decline reflects a combination of persistent margin headwinds, tariff-policy uncertainty, and a generally cautious backdrop for small-cap names. Nephros also carries company-specific risks: three customers accounted for about 44% of 2025 revenue, and the company relies on a single exclusive supplier for key filtration materials. These factors, together with limited trading liquidity, have contributed to the stock's extended slide from its mid-August levels.
Key Areas to Monitor Going Forward
Looking ahead, investors are likely to focus on several factors. First, the company's fourth-quarter and full-year 2026 results will provide the next read on whether revenue growth and profitability momentum can continue, and whether gross margins stabilize or face further pressure from tariffs, shipping costs, and product mix. Second, progress on expanding the active customer base—which reached a record 1,766 sites in Q3—and on service-revenue growth will be closely watched.
Additional items to monitor include the company's reliance on a single supplier, remediation of a previously disclosed internal-control weakness related to revenue recognition, and customer concentration. Analyst sentiment remains constructive, with a reported average price target near $6.25 versus the current share price, but small-cap liquidity, tariff policy, and broader market risk appetite will likely continue to influence near-term volatility. One thing that stands out is how these company-specific risks could amplify moves in either direction.
Exploring Data-Driven Trading Approaches
In my view, tools that surface systematic signals can complement traditional research when evaluating names like this. Tickeron’s AI Trading Bots provide one way to review a range of strategies across different timeframes and performance metrics, allowing investors to see curated examples of data-driven ideas without manually reviewing every option available.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NEPH's Stochastic Oscillator is sitting in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NEPH's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEPH advanced for three days, in 164 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
NEPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NEPH as a result. In 81 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for NEPH turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 31 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
The 10-day moving average for NEPH crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for NEPH entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 53 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.532) is normal, around the industry mean (4.964). P/E Ratio (17.438) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.318) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. NEPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system
Industry PharmaceuticalsOther
Advertisement